Vaccination of COVID‐19 convalescent plasma donors increases binding and neutralizing antibodies against SARS‐CoV‐2 variants
Abstract
COVID‐19 convalescent plasma (CCP) was widely used as passive immunotherapy during the first waves of SARS‐CoV‐2 infection in the US. However, based on observational studies and randomized controlled trials, the beneficial effects of CCP were limited, and its use was virtually discontinued early in 2021, in concurrence with increased vaccination rates and availability of monoclonal antibody (mAb) therapeutics. Yet, as new variants of the SARS‐CoV‐2 spread, interest in CCP derived from vaccine‐boosted CCP donors is resurging. The effect of vaccination of previously infected CCP donors on antibodies against rapidly spreading variants is still under investigation.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Feb 13, 2022
- Source ID
- 10.1111/trf.16823
Entities
People
- Chloe Thorbrogger
- Clara Di Germanio
- Graham Simmons
- Mars Stone
- Michael P. Busch
- Rachel Martinelli
- Thomas Gniadek
Organizations
- Inger Rice Foundation
- NorthShore University HealthSystem
- United States Department of Defense
- University of California, San Francisco